Caspofungin Eberth
Powder for concentrate for solution for infusion
Caspofungin Eberth
dosage/strength | dosage form | pack size |
| pharmaceutical registration number | SmPC |
|---|---|---|---|---|---|
50 mg | powder for concentrate for solution for infusion | 1 vial | N1 | 18501234 |
|
70 mg | powder for concentrate for solution for infusion | 1 vial | N1 | 18501240 |
|
Active substance:
Caspofungin (as acetate)
Pharmacotherapeutic group:
Antimycotics for systemic use; Other antimycotics for systemic use
ATC code: J02AX04
Mechanism of action:
Caspofungin acetate is a semi-synthetic lipopeptide (echinocandin) compound synthesised from a fermentation product of Glarea lozoyensis. Caspofungin acetate inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi and yeast. Beta (1,3)-D-glucan is not present in mammalian cells.
Fungicidal activity with caspofungin has been demonstrated against Candida yeasts. Studies in vitro and in vivo demonstrate that exposure of Aspergillus to caspofungin results in lysis and death of hyphal apical tips and branch points where cell growth and division occur.
Therapeutic indications:
- Treatment of invasive candidiasis in adult or paediatric patients.
- Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
- Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropenic adult or paediatric patients.